HDAC9 and Thrombocytopenia: Since previous clinical trials using pan-HDAC inhibitors reported adverse effects such as leukocytopenia, thrombocytopenia, gastrointestinal symptoms, and QT interval prolongation [42], a more targeted approach may be needed to improve the safety profile of this class of drugs.